SEC Filing Summary
Registrant and period: The supplied Form 10-Q is for Neuralstem, Inc., not Palisade Bio, Inc. It covers the three and six months ended June 30, 2019, with comparative periods ended June 30, 2018. The financial statements are unaudited and reflect a 1-for-20 reverse stock split completed July 17, 2019.
Business Context
Neuralstem was a clinical-stage biopharmaceutical company developing human neural stem-cell therapies and small-molecule compounds for central nervous system diseases. Its principal programs were NSI-566 for ALS, ischemic stroke and chronic spinal cord injury, and NSI-189 for major depressive disorder. The company also pursued in-licensing and acquisition opportunities. It had five full-time employees as of July 31, 2019.
Key Financial Metrics
| Metric | Three months ended June 30, 2019 | Six months ended June 30, 2019 |
|---|---|---|
| Revenue | $7,894 | $10,394 |
| Research and development expense | $954,453 | $2,468,916 |
| General and administrative expense | $971,822 | $1,916,424 |
| Operating loss | $1,918,381 | $4,374,946 |
| Net loss | $1,436,921 | $4,550,913 |
| Net loss per share | $1.45 | $4.78 |
| Net cash used in operating activities | Not separately presented | $3,309,508 |
Revenue consisted primarily of small intellectual-property license fees and, in the 2019 second quarter, approximately $5,400 of settlement-related royalties. The company generated no revenue from commercial product sales. Gross and operating margins are not meaningful because revenue was nominal relative to research and development and administrative spending.
- Cash and cash equivalents were $2.3 million at June 30, 2019, down from $5.8 million at December 31, 2018.
- Total current assets were $2.7 million and current liabilities were $1.1 million, implying working capital of approximately $1.6 million based on the balance sheet presented.
- Total liabilities were $1.6 million, including $487,723 of warrant liabilities at fair value. The filing does not present material conventional long-term debt at June 30, 2019; financing cash outflows included $195,869 of payments on short-term notes.
- Stockholders’ equity declined to $2.0 million from $6.0 million at December 31, 2018, while accumulated deficit reached $218.2 million.
- Share-based compensation expense was $466,744 for the first six months of 2019.
Changes Versus Prior Comparable Period
- Six-month revenue fell to $10,394 from $255,000, primarily because the prior-year period included $250,000 of settlement-related royalties.
- Second-quarter revenue declined to $7,894 from $252,500, also reflecting the absence of the prior-year settlement royalty.
- Six-month research and development expense increased 13% to $2.5 million, driven by severance, strategic-alternatives consulting and higher share-based compensation, partly offset by lower clinical-trial costs and higher grant reimbursements.
- Six-month general and administrative expense decreased 22% to $1.9 million because of cost-cutting measures, including lower consulting, professional, tax and insurance costs.
- Six-month net loss increased to $4.6 million from $2.8 million, primarily because 2018 benefited from a larger non-cash warrant fair-value gain and 2019 included a $368,000 write-off of a related-party receivable.
- Cash used in operating activities improved to $3.3 million from $4.4 million, but cash declined by $3.5 million during the first six months of 2019. The prior-year period included $5.0 million of proceeds from maturing short-term investments.
Guidance, Outlook, Risks and Unusual Items
- Management stated that existing cash, including approximately $6.6 million of net proceeds from a July 31, 2019 underwritten offering, was expected to fund operations into the third quarter of 2020 under current plans.
- The filing nevertheless states that substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements. Additional financing was required, and no future funding commitments existed.
- The July 2019 offering generated approximately $7.5 million of gross proceeds and $6.6 million of expected net proceeds through common shares, prefunded warrants and short- and long-term warrants. Proceeds were intended for product development, acquisitions and in-licensing, and general corporate purposes.
- Management had curtailed most preclinical and clinical development because of limited cash, while continuing an exploratory Phase 2 ischemic-stroke study of NSI-566 and grant-funded activities. The company stated that the ischemic-stroke study results were not expected to support a regulatory submission.
- NSI-189’s Phase 2 major-depressive-disorder study failed to meet its primary efficacy endpoint, although certain secondary and patient-reported measures showed favorable results. No product candidate had received regulatory approval.
- Material risks included continued operating losses, dependence on equity financing, potential dilution, clinical and regulatory failure, reliance on third-party manufacturers and clinical research providers, intellectual-property challenges, limited personnel, stock-price volatility and potential Nasdaq delisting.
- The company completed the 1-for-20 reverse stock split to address Nasdaq’s minimum bid-price deficiency; Nasdaq granted continued listing on August 6, 2019.
- A former executive’s related-party reimbursement receivable was modified in March 2019, approximately 50% was forgiven, and the remaining $229,000 balance was fully reserved as unrecoverable.
- The filing states that disclosure controls were effective as of June 30, 2019 and that no material changes in internal control over financial reporting occurred during the quarter.
Investor Verification Items
- Verify the issuer identity: the supplied filing is for Neuralstem, Inc., whereas the request identifies Palisade Bio, Inc.
- Confirm the post-quarter capitalization, including shares and warrants issued in the July 2019 offering and the effect of the reverse stock split.
- Assess whether the stated cash runway to the third quarter of 2020 remains credible given the company’s operating cash burn and dependence on additional financing.
- Review the going-concern qualification and the terms, exercise conditions and potential dilution from outstanding warrants and preferred stock.
- Evaluate the status, funding and regulatory relevance of the NSI-566 clinical programs and the consequences of the failed primary endpoint for NSI-189.
- Reconcile the filing’s descriptions of the quarterly and six-month warrant fair-value adjustments, which have inconsistent gain/loss wording between the financial statements and MD&A.